Human Immunodeficiency Virus type 1 (HIV-1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Human Immunodeficiency Virus type 1 (HIV-1) Market Outlook

Thelansis’s “Human Immunodeficiency Virus type 1 (HIV-1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Human Immunodeficiency Virus type 1 (HIV-1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Human Immunodeficiency Virus type 1 (HIV-1) Overview

Human Immunodeficiency Virus type 1 (HIV-1) is a retrovirus that infects humans and is the primary cause of acquired immunodeficiency syndrome (AIDS). It belongs to the Lentivirus genus of the Retroviridae family. HIV-1 is one of the two major types of HIV, the other being HIV-2. HIV-1 is transmitted by exchanging body fluids, including blood, semen, vaginal fluids, rectal fluids, and breast milk. The most common transmission routes include unprotected sexual contact with an infected person, sharing needles or syringes with an infected person, and transmission from an infected mother to her child during childbirth or breastfeeding. Once the virus enters the body, it primarily targets and infects CD4+ T cells, a type of white blood cell crucial for the immune system’s proper functioning. As the virus replicates, it progressively destroys these CD4+ T cells, weakening the immune system and making the person more susceptible to opportunistic infections and certain cancers. The course of HIV infection is divided into several stages:

1. Acute HIV infection: This occurs within a few weeks after the initial infection and may cause flu-like symptoms such as headache, fever, sore throat, swollen lymph nodes, and rash.
2. Clinical latency: After the initial stage, HIV remains in the body but may not cause noticeable symptoms for an extended period. However, the virus continues to replicate and damage the immune system during this time.
3. Acquired Immunodeficiency Syndrome (AIDS): If HIV is left untreated, the immune system becomes severely damaged, and the person is diagnosed with AIDS. At this stage, the individual becomes highly susceptible to opportunistic infections and certain cancers.

HIV can be managed effectively with antiretroviral therapy (ART), a combination of medications that helps suppress viral replication and maintain a healthy immune system. While ART does not cure HIV, it allows people living with the virus to lead relatively healthy lives and significantly reduces the risk of transmitting it to others.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Human Immunodeficiency Virus type 1 (HIV-1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034